12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

Laboratoire francais, NanoCarrier deal

NanoCarrier and LFB mutually agreed to temporarily discontinue an October 2010 deal to develop a long-lasting form of recombinant human coagulation Factor VIIa (rhFVIIa) to treat hemophilia. The product uses LFB's rhFVIIa in combination...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >